[pubmed] Clinical profile and impact of co-morbidities in patients with very-late onset myasthenia gravis

[RSS-Bot]

Muscle Nerve. 2021 Jul 7. doi: 10.1002/mus.27369. Online ahead of print.

ABSTRACT

INTRODUCTION/AIMS: The aim of the study was to evaluate the clinical profile of myasthenia gravis (MG) in older patients and to determine the impact of medical comorbidities on their MG status and outcome.

METHODS: This was a retrospective chart review of patients with a symptom onset of MG at or above the age of 65 years. Correlations were done between demographics, clinical characteristics, the Myasthenia Gravis Foundation of America (MGFA) severity scale and Myasthenia Gravis Impairment Index (MGII) with two outcome measures- Myasthenia Gravis Foundation of America (MGFA)-Post Intervention Status (PIS) and Simple Single Question (SSQ).

RESULTS: The study population included 109 patients with 90 of them having more than one follow-up. The mean age was 75.3±6.9 years and sex distribution was even. 67.7% of patients had generalized MG. Nine-one percent of patients had one co-morbidity. None of the demographic factors or comorbidities showed an association with MGFA-PIS, SSQ or MGII after correction for multiple comparisons. 71% improved with treatment, 12.4% remained unchanged and 16.6% of patients worsened at their last follow-up visit.

DISCUSSION: Our study showed that patients with very-late onset MG have a good prognosis and treatment response. None of the comorbidities had an impact on the severity of myasthenic symptoms or . on the outcome in these patients.

PMID:34235762 | DOI:10.1002/mus.27369


Source: https://pubmed.ncbi.nlm.nih.gov/3423576 ... 3&v=2.14.5